Domov › Trojnásobne negatívny karcinóm prsníka › Michigan
Klinické štúdie Trojnásobne negatívny karcinóm prsníka v štáte Michigan
28 štúdií pre Trojnásobne negatívny karcinóm prsníka hľadá účastníkov v zariadeniach v štáte Michigan.
Mestá v štáte Michigan
Oficiálny text štúdie (anglicky)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06270706A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06465069177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- BAMF Health, Grand Rapids
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT07189871First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- Karmanos Cancer Institute, Detroit
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT06799065A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Cancer & Hematology Centers of Western Michigan ( Site 0026), Grand Rapids
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06841354Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- University of Michigan ( Site 0103), Ann Arbor
- Henry Ford Health ( Site 0010), Detroit
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06393374A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- BAMF Health, Grand Rapids
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT07020117Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
- START Midwest, Grand Rapids
Prebieha náborFáza 1
Vek 18 a viac · Ženy · Aktualizované 10. 9. 2026 · NCT07652242Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
- William Beaumont Hospital, Royal Oak
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT05633654A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT06400472Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Trinity Health, Ann Arbor
Prebieha náborObservačná štúdia
Vek 18 až 99 · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT07211178A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 8. 2026 · NCT07029399A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Grand Rapids
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 19. 8. 2026 · NCT07115043Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 8. 2026 · NCT05985655A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 8. 2026 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 8. 2026 · NCT05579366Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- BAMF Health, Grand Rapids
Prebieha náborFáza 1
Vek 18 až 100 · Všetky pohlavia · Aktualizované 29. 7. 2026 · NCT06562192A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
- Karmanos Cancer Institute, Farmington Hills
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 7. 2026 · NCT05208762A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- START Midwest, LLC, Grand Rapids
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 7. 2026 · NCT07318805A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Henry Ford Health Hospital, Detroit
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 6. 2026 · NCT05377996Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- START Midwest /ID# 248685, Grand Rapids
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 6. 2026 · NCT05005403A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Karmanos Cancer Institute, Detroit
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 6. 2026 · NCT07503808BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- University of Michigan, Ann Arbor
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 6. 2026 · NCT05768932I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Herbert-Herman Cancer Center, Sparrow Hospital, Lansing
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 6. 5. 2026 · NCT01042379JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Henry Ford Health System, Detroit
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 1. 2026 · NCT05490472A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- University of Michigan, Ann Arbor
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 11. 2025 · NCT05902988A Beta-only IL-2 ImmunoTherapY Study
- Karmanos Cancer Institute, Detroit
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 7. 2025 · NCT05086692CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Trinity Health-Michigan, Ypsilanti
Prebieha náborObservačná štúdia
Vek 18 a viac · Ženy · Aktualizované 7. 1. 2025 · NCT06230185Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.